Opinion

Video

The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Focusing on elacestrant, Dr Graff discusses the role of oral SERDs (selective estrogen receptor degraders) in the treatment of patients with ER+/HER2- metastatic breast cancer.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Dr Elise Tremblay
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo